Ionis Pharmaceuticals

Highly Engaged Employees

Ionis Pharmaceuticals, established in 1989, is a leading commercial-stage biotechnology company dedicated to discovering and developing RNA-targeted medicines. Headquartered in Carlsbad, California, the company has pioneered antisense therapy technology, alongside RNA interference and CRISPR therapeutics. Ionis focuses on creating first-in-class and best-in-class treatments for severe diseases across cardiovascular, metabolic, neurological, and rare genetic conditions, as well as oncology. Its proprietary antisense technology platform is central to its strategy, enabling the modulation of protein production by targeting RNA.

Operating with a workforce of 1,000-5,000 employees across 7 locations, Ionis Pharmaceuticals leverages its advanced technology to address significant unmet medical needs. The company's scientific approach targets the root cause of diseases at the RNA level, facilitating the development of novel therapeutics. Ionis's commitment extends to rigorous clinical development and regulatory processes to bring innovative medicines to patients. Learn about Ionis Pharmaceuticals's global headquarters for more on its operational base. Meet Ionis Pharmaceuticals's team to understand the expertise driving its research and development efforts.

With a reported revenue of $1.1B, Ionis Pharmaceuticals demonstrates substantial market presence and financial capacity. The company has secured significant funding, including a $201.25 million debt financing in 2012, to fuel its extensive research and development pipeline. Ionis competes in a dynamic biopharmaceutical landscape with key players such as Vertex, Alnylam Pharmaceuticals, and Sarepta Therapeutics, among others. This competitive positioning underscores Ionis's role in advancing RNA-based therapeutics. Explore financial highlights for a deeper dive into its fiscal performance and market valuation.